reports
- Tushar Manudhane
MOSL: LAURUS LABS (Buy)- 1QFY23 beats estimates and is progressing wel...
Laurus Lab (LAURUS) delivered better-than-expected 1QFY23 performance fueled by strong growth momentum in the Synthesis (CDMO) segment. LAURUS is on track to incur capex in Synthesis/bio division/Non-ARV formulation (FDF) to cater to business growth over the next 3-5 years. We have tweaked our EPS estimates by -4%/-3% for FY23/FY24 to factor in higher tax rate. We expect 34% earnings CAGR over FY22-24. We continue to value the stock at 23x 12M forward earnings to arrive at our TP of INR680. ...
LAURUS LABS reduced its risk exposure resulting in an upgrade to Posit...
LAURUS LABS (IN), a company active in the Pharmaceuticals industry, reduced its market risk and raised its general evaluation. The independent financial analyst theScreener awarded an improved star rating to the company, which now shows 3 out of 4 possible stars; its market behaviour has improved and can be considered as defensive. theScreener believes that this new assessment merits an overall rating upgrade to Positive. As of the analysis date March 25, 2022, the closing price was INR 589.80 a...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.